The long-term strategy for AI in drug discovery is a two-step process. First, create an AI platform to design effective drugs. Second, after a dozen or so AI-designed drugs succeed, use that data to convince regulators to trust AI predictions, potentially allowing future drugs to skip steps like animal testing and accelerate trials.

The integration of AI in drug development has been extraordinarily fast. What were vague, 'hand wavy' AI/ML claims on pitch decks just 3-4 years ago have, since ChatGPT's 2022 arrival, become a fundamental, end-to-end retooling of how the industry discovers and develops drugs.

The convergence of AI, massive health datasets, and genomics is creating a new paradigm in medicine. Instead of lengthy human trials, AI will prove drug solutions and create personalized therapeutics by analyzing an individual's condition against millions of data points, dramatically accelerating medical breakthroughs.

After a year of extensive experimentation, major pharmaceutical companies are now adopting AI at scale, marked by large-scale deals with AI tooling companies. This signals a market inflection point where pharma is moving beyond testing and is actively deploying AI across R&D and commercial functions after seeing demonstrable ROI.

The nature of AI discussions in biopharma has rapidly evolved from theoretical potential to practical, daily integration of tools like Claude. This acceleration in the last six months means AI fluency is no longer a future goal but an immediate operational necessity for any company hoping to remain competitive in drug development.

Current patient selection for radioligand therapies often relies on a simple binary 'positive' or 'negative' assessment, which fails to predict response 55% of the time. AI moves beyond this by providing quantitative, whole-body tumor assessments to predict who will actually respond to treatment, a far more critical factor for clinical and commercial success.

As AI tools increasingly guide patient diagnosis and treatment recommendations, pharma's focus must shift. The primary challenge is no longer just influencing the HCP directly, but ensuring your product data is structured to "win" in the AI's algorithmic suggestions.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.

Similar to how the rise of the internet forced every retail company to adopt e-commerce, the advancement of AI will mandate that every surviving pharmaceutical company becomes 'AI-native.' This isn't an optional upgrade but a fundamental business model shift necessary for survival in the coming years.